65,437 trials
Recurrent Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate Using Response Evaluation Criteria in Solid Tumors Version 1.1 — 2; 18; 14; 1 Participants
Alveolar Bone Loss · Periodontal Diseases
Primary: Number of Participants That Met the Success Criteria of Radiographic and Clinical Measurements — 16; 15; 19; 17 Participants
Non-alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis · NASH - Nonalcoholic Steatohepatitis
Primary: Number of Participants With Hepatic Histological Improvement in NAS — 22; 25; 27; 34 Participants — p=0.747
Fluid Overload
Primary: Heart Rate at T0 — 85.23; 88.833 beats per minute — p=.443
Colorectal Carcinoma
Primary: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor — 32.8; 34.9 Percentage of participants
Coronary Artery Disease
Primary: Platelet Reactivity Unit — 177; 164; 174; 26 PRU — p=>0.05
Plaque Psoriasis
Primary: The Percentage of Participants With Treatment Success at Week 8 — 35.76; 6.98 percentage of participants
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs) — 0; 0; 0; 0 Participants
DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma · DS Stage III Plasma Cell Myeloma
Primary: Rate of Complete Response as Determined by the IMWG Criteria — 2 Participants
Multiple Myeloma
Primary: Number of Participants at Each Response Category (Stable Disease, Minimal Response, Partial Response, Very Good Partial Response, Near Complete Response/Complete…
Constipation
Primary: Percentage of Participants Witn Spontaneous Bowel Movements Within 3 Hours of Treatment — 2; 3; 2; 5 Participants
Psoriasis
Primary: Percent of Subjects With Treatment Success — 32.79; 33.97; 0; 7.14 percentage of participants
Coronary Artery Disease
Primary: Platelet Reactivity — 36; 33 PRU
Lupus Erythematosus, Systemic
Primary: Physician's Global Assessment (PGA) — 58.8; 60.6; 33.2; 30.2 score on a scale
Adenocarcinoma of the Lung
Primary: Progression-free Survival (PFS) — 5.8; 4.7; 5.9; 4.7 Months — p=0.3519